16,083 Shares in Miragen Therapeutics, Inc. (MGEN) Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. bought a new stake in Miragen Therapeutics, Inc. (NASDAQ:MGEN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 16,083 shares of the medical research company’s stock, valued at approximately $147,000. Russell Investments Group Ltd. owned 0.07% of Miragen Therapeutics at the end of the most recent quarter.

Separately, BSW Wealth Partners purchased a new position in shares of Miragen Therapeutics in the 3rd quarter valued at $203,000. Institutional investors own 22.64% of the company’s stock.

In related news, Director Thomas E. Hughes sold 12,000 shares of Miragen Therapeutics stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $8.00, for a total transaction of $96,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 44.40% of the company’s stock.

MGEN has been the topic of a number of research reports. Chardan Capital reissued a “buy” rating and issued a $29.00 target price on shares of Miragen Therapeutics in a research note on Monday, October 16th. Zacks Investment Research raised shares of Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Thursday, October 19th. Wedbush reissued a “buy” rating and issued a $19.00 target price on shares of Miragen Therapeutics in a research note on Friday, December 1st. Finally, B. Riley initiated coverage on shares of Miragen Therapeutics in a research note on Friday. They issued a “buy” rating and a $15.50 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $17.88.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) opened at $8.56 on Tuesday. Miragen Therapeutics, Inc. has a one year low of $4.76 and a one year high of $18.00. The company has a quick ratio of 7.11, a current ratio of 7.11 and a debt-to-equity ratio of 0.04. The company has a market cap of $203.02, a price-to-earnings ratio of 57.07 and a beta of 1.91.

Miragen Therapeutics (NASDAQ:MGEN) last released its quarterly earnings results on Wednesday, November 8th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.12. Miragen Therapeutics had a negative net margin of 720.38% and a negative return on equity of 80.31%. The firm had revenue of $1.63 million for the quarter, compared to the consensus estimate of $0.72 million. sell-side analysts forecast that Miragen Therapeutics, Inc. will post -1.39 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “16,083 Shares in Miragen Therapeutics, Inc. (MGEN) Purchased by Russell Investments Group Ltd.” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.com-unik.info/2018/01/09/16083-shares-in-miragen-therapeutics-inc-mgen-purchased-by-russell-investments-group-ltd.html.

About Miragen Therapeutics

Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.

Institutional Ownership by Quarter for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit